Abstract
‘Poison can be employed as a means for destruction of life or as a treatment for the sick’. Such is the case with botulinum toxin type A, said Dr Roger Aoki from Allergan Inc., US, speaking at the 4th Congress of the European Federation of Neurological Societies [Lisbon, Portugal; September 1999]. Allergan’s botulinum toxin type A purified neurotoxin complex [‘BOTOX’] provides a particularly effective approach to the localised treatment of disorders associated with muscle overactivity, with neglible adverse effects. Some of the most recent data on the use of botulinum toxin type A in such indications were discussed at the congress.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
